Cargando…

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

INTRODUCTION: Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period. CASE PRESENTATION: We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine. CONCLU...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Qian-Ya, Zhang, Xiao-Dong, Hu, Ze-Di, Huang, Shi-Shi, Zhu, Shi-Guo, Chen, Cai-Ping, Zhang, Xiong, Wang, Jian-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561359/ https://www.ncbi.nlm.nih.gov/pubmed/36247788 http://dx.doi.org/10.3389/fneur.2022.961758

Ejemplares similares

Amantadine ER (Gocovri(®)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
por: Hauser, Robert A., et al.
Publicado: (2021)

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
por: Sawada, Hideyuki, et al.
Publicado: (2010)

An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
por: Kong, Min, et al.
Publicado: (2017)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Impaired Topographic Organization in Patients With Idiopathic Blepharospasm
por: Hou, Yanbing, et al.
Publicado: (2022)

Factors Associated With Dyskinesia in Parkinson's Disease in Mainland China
por: Zhou, Xun, et al.
Publicado: (2019)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
por: Kim, Aryun, et al.
Publicado: (2018)

Altered functional connectivity of cerebellar dentate nucleus in peak-dose dyskinesia in Parkinson’s disease
por: Zhang, Heng, et al.
Publicado: (2022)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Smell and taste in idiopathic blepharospasm
por: Gamain, Julie, et al.
Publicado: (2021)

Tardive Dyskinesia Following Low-Dose Risperidone
por: Rokon, Ahmad E, et al.
Publicado: (2022)

Screening Gene Mutations in Chinese Patients With Benign Essential Blepharospasm
por: Dong, Hongjuan, et al.
Publicado: (2020)

Blepharospasm, Oromandibular Dystonia, and Meige Syndrome: Clinical and Genetic Update
por: Ma, Hongying, et al.
Publicado: (2021)

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
por: Mehta, Shyamal H., et al.
Publicado: (2021)

Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2021)

Improvement of Deep Brain Stimulation in Dyskinesia in Parkinson's Disease: A Meta-Analysis
por: Liu, Yun, et al.
Publicado: (2019)

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
por: Elmer, Lawrence W., et al.
Publicado: (2018)

Altered Functional Connectivity and Sensory Processing in Blepharospasm and Hemifacial Spasm: Coexistence and Difference
por: Fang, Ting-Chun, et al.
Publicado: (2021)

Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia
por: Sgroi, Stefania, et al.
Publicado: (2018)

Transcranial Magnetic Stimulation Alleviates Levodopa-Induced Dyskinesia in Parkinson's Disease and the Related Mechanisms: A Mini-Review
por: Wu, Yi, et al.
Publicado: (2021)

Amantadine, COVID-19 and Parkinsonism
por: Wiwanitkit, Viroj
Publicado: (2020)

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2021)

Pantothenate Kinase-Associated Neurodegeneration (PKAN) With Concomitant Blepharospasm: Unveiling a Clinical Enigma
por: Reddy, Venkat, et al.
Publicado: (2023)

Functional connectivity alterations in the frontoparietal network and sensorimotor network are associated with behavioral heterogeneity in blepharospasm
por: Huang, Xiao-Feng, et al.
Publicado: (2023)

Effect of Pre-exposure Use of Amantadine on COVID-19 Infection: A Hospital-Based Cohort Study in Patients With Parkinson's Disease or Multiple Sclerosis
por: Kamel, Walaa A., et al.
Publicado: (2021)

Concussion-Induced Oromandibular Dyskinesia
por: Zhang, Brenda, et al.
Publicado: (2023)

High dose amantadine therapy may cause increased falling in patients with Parkinson's disease: A case report
por: Dames, Bridget, et al.
Publicado: (2020)

Evaluation of the Direct Effect of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus on Levodopa-Induced On-Dyskinesia in Parkinson's Disease
por: Li, Jiping, et al.
Publicado: (2021)

Cardinal Motor Features of Parkinson’s Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia
por: Goubault, Etienne, et al.
Publicado: (2018)

Elucidation of the mechanism underlying impaired sensorimotor gating in patients with primary blepharospasm using prepulse inhibition
por: Hao, Xinqing, et al.
Publicado: (2023)

SLC6A4 Repeat and Single-Nucleotide Polymorphisms Are Associated With Depression and Rest Tremor in Parkinson's Disease: An Exploratory Study
por: Wang, Jian-Yong, et al.
Publicado: (2019)

Gray Matter Structural and Functional Alterations in Idiopathic Blepharospasm: A Multimodal Meta-Analysis of VBM and Functional Neuroimaging Studies
por: Zhang, Meng, et al.
Publicado: (2022)

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020)

Response to: Amantadine, COVID-19 and Parkinsonism
por: Aranda-Abreu, Gonzalo Emiliano
Publicado: (2020)

The Effect of Amantadine on Agitation in the Pediatric Traumatic Brain Injury Population: A Case Series
por: Hon, Emily, et al.
Publicado: (2023)

Corrigendum: Elucidation of the mechanism underlying impaired sensorimotor gating in patients with primary blepharospasm using prepulse inhibition
por: Hao, Xinqing, et al.
Publicado: (2023)

Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living
por: Goubault, Etienne, et al.
Publicado: (2019)

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
por: Aljuaid, Maram, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_75eegk7jb62ilo066blvoqb6rn